Dr. Motesharei brings over 20 years of experience in management, strategy, business development, alliance management, product development and marketing across the biotechnology and pharmaceutical industry.
Ariana is pleased to announce that the company has joined the Healthcare Data Institute. The Healthcare Data Institute is the first international think tank dedicated to Big Data in the health sector. An Orange Healthcare initiative, the Healthcare Data Institute was launched in partnership with other companies representative of the Big Data health ecosystem: […]
Interview with Mohammad Afshar – CEO, Ariana Pharma, France, 12 July 2016 Mohammad Afshar, CEO of Ariana Pharma, shares his insights on the importance of decision support tools, big data’s impact on the healthcare industry, and the need to translate this data into the production of real products. He also discusses the challenges he faced […]
Ariana hosted their regular Science Day this week – a 1-day symposium in Paris on advances in machine learning and artificial intelligence, chaired by Dr Jean Sallantin, Director of Research at the CNRS LIRMM (Laboratoire d’Informatique, de Robotique et de Micro-électronique de Montpellier) and Scientific Advisor to Ariana. As ever, this was a stimulating […]
The Ariana Running Team are pleased to participate in the popular NoFinishLine Paris 2016 charitable fun run event in support of sick and homeless children. Ariana Running Team at NoFinishLine Paris 2016 (Left to right): Sébastien Vaucouleur, Isabelle Chaduteau, Dan Manak, Mohammad Afshar, Yannic Tognetti, Frédéric Parmentier (11254), David Morley, Vincent Récamier, Julie Miralves, […]
Dr Mohammad Afshar (Founder and CEO) is joining a prestigious panel of industry leaders to discuss the strategy of open data, data intelligence and data management. Genevieve Fioraso, France’s Deputy Minister for Higher Education & Research and Axelle Lemaire, Deputy Minister in charge of digital tech will participate in the session. Making Sense of BIG […]
Specialist Company Strives to Improve Patient Selection and Treatment Outcomes. Ariana Pharma exhaustively mines and analyzes multiparametric data (biochemical, genomic, proteomic, genetic, metabolic, imaging, clinical, etc.) to identify patient responders and reduce clinical and drug development risks. The process generates actionable information using fewer biomarker signatures than traditional data-mining methods, improving both efficiency and efficacy. […]
Une start-up française qui apporte un support technique à la Food and Drug Administration (FDA), c’est tout à fait dérogatoire. C’est pourtant le cas d’ Ariana Pharma, une petite société française spécialisée dans les applications pharmaceutiques du « data mining ». Links: Read online